Patent intelligence · US
US 6869968
2-(3H)-oxazolone derivatives and their use as COX-2 inhibitors
2-(3H)-oxazolone derivatives and their use as COX-2 inhibitors
Patent details — US 6869968
- Jurisdiction
- US
- Status
- expired
- Grant date
- Mar 22, 2005
- Expiration
- Mar 17, 2025
- Applicant
- Allmirall Prodesfarma S.A.
- Claims
- 52
- CPC classes
- A61P, A61P11/00, A61P11/06, A61P29/00
Quick answer
US 6869968 (2-(3H)-oxazolone derivatives and their use as COX-2 inhibitors) is held by Allmirall Prodesfarma S.A.. Status: expired. Granted Mar 22, 2005. Expires Mar 17, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Allmirall Prodesfarma S.A.
- Grant date
- Expiration
- Claims
- 52
- CPC classes
- A61P, A61P11/00, A61P11/06, A61P29/00, A61P35/00, A61P43/00
More from Allmirall Prodesfarma S.A.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 6869968?
US 6869968 (2-(3H)-oxazolone derivatives and their use as COX-2 inhibitors) is held by Allmirall Prodesfarma S.A.. Status: expired. Granted Mar 22, 2005. Expires Mar 17, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6869968?
Allmirall Prodesfarma S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 6869968 expire?
Our index shows an expiration date of Mar 17, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.